Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2016

View Archived Issues

Zinc-13407541 partially reverses hypophosphatemic effects of excess FGF-23 in vivo

Janssen initiates phase IIb study of simeprevir, odalasvir and AL-335 for HCV

IL-31 levels are upregulated in dermatomyositis

PRMT5 inhibitors could represent new therapeutic approach in treatment of psoriatic diseases

Hetero Research Foundation patents antiviral agents

Blueprint Medicines reports data from ongoing phase I trial of BLU-554 in HCC

FDA gives fast track designation to Epizyme's tazemetostat

Sichuan Haisco Pharmaceutical discloses M3 receptor antagonist and/or beta2-adrenoreceptor agonists

Bristol-Myers Squibb describes bromodomain inhibitors

FDA accepts sBLA for Keytruda in patients with MSI-H cancer

Kancera develops HDAC inhibitors

European Commission approves Glyxambi for type 2 diabetes

Phase II trial of cavosonstat in cystic fibrosis does not meet primary endpoint

EMA grants full aproval to vismodegib

Oxford BioMedica establishes strategic alliance with Orchard Therapeutics

Mutations in FAM105B gene may be involved in autoinflammatory diseases

GTx's enobosarm achieves primary efficacy endpoint in phase II trial

Inisync available in Japan

Idera and Vivelix sign license and collaboration agreement for IMO-9200

MonoSol files NDA with FDA for Tadalafil PharmFilm in the treatment of erectile dysfunction

Cyfip2 is a genome-wide significant genetic factor for binge eating

Galapagos initiates phase I study of GLPG-2737 in cystic fibrosis

Relypsa's patiromer gains FDA approval of sNDA, black box warning removed from label

Recro Pharma discloses positive results from phase III trial of i.v. meloxicam

VB-037 shows promise in EAE model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...